Adolescent and Young Adult Oncology (AYAO) Patient Enrollments Onto National Cancer Institute (Nci)-Supported Trials from 2000 to 2010.

10058 Background: Lack of participation in clinical trials has been proposed as a key explanation for the survival deficit of AYAO patients. We compared the proportion of newly diagnosed AYAO patients (out of all patients) enrolled on NCI-sponsored cooperative group therapeutic trials from 2000 to 2010 to the proportion that would be expected based on SEER incidence data. Location of care was also assessed. Methods: We studied AYAO accrual to all open trials by evaluating two age groups (15-19 and 20-39 years) and two time periods (2000-2005 and 2006-2010). For each cancer type, the observed proportion of AYAO patients was calculated by dividing the total number of AYAO participants accrued by the total number of trial participants. This was compared to SEER 17 data by calculating the same proportion using the cancer specific incidence for the same age and year groupings. The proportion of community based (CCOP) accrual to non-CCOP accrual was compared for the AYAO patients. Results: Of 116,665 patients enrolled from 294 NCI-sponsored studies with eighteen cancer types, 12,392 were aged 15-39 years. For both time periods, the observed proportion of 15 - 19 year olds was greater than the SEER data for ALL, AML, CNS, Hodgkins, and bone cancers while the clinical trial proportion of 20-39 year olds exceeded the SEER data for AML, colon, NHL, and breast cancer. Among CCOPs, the proportion of AYAO accrual was greater for younger than older patients in ALL, bone cancer, Hodgkin, and STS. Conclusions: For many cancer types, both adolescent and young adult patient enrollments onto NCI studies exceed what would be expected based on SEER incidence data. Although AYAO patients are represented on clinical trials, recruiting and ensuring trials are available for this age group should remain a priority.